OTCMKTS:IPIX Innovation Pharmaceuticals (IPIX) Stock Price, News & Analysis $0.0010 +0.00 (+42.86%) As of 12:35 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartSEC FilingsBuy This Stock About Innovation Pharmaceuticals Stock (OTCMKTS:IPIX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get IPIX alerts:Sign Up Key Stats Today's Range$0.0010▼$0.001050-Day Range N/A52-Week Range$0.0001▼$0.0187Volume104,501 shsAverage Volume160,379 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Innovation Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops small molecule therapies to treat inflammatory diseases, cancer, dermatology, and anti- infective. Its lead drug candidate is Brilacidin, a therapeutic for the treatment of oral mucositis, inflammatory bowel disease, acute bacterial skin and skin structure infection, and COVID-19. The company has a license agreement with Alfasigma S.p.A.; and collaborative research agreement with Fox Chase Chemical Diversity Center, Inc. The company was formerly known as Cellceutix Corporation and changed its name to Innovation Pharmaceuticals Inc. in June 2017. Innovation Pharmaceuticals Inc. was incorporated in 2005 and is headquartered in Wakefield, Massachusetts. Read More Receive IPIX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Innovation Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address IPIX Stock News HeadlinesInnovation, pharma profits won't suffer under Trump prescription drug EO - White HouseMay 12, 2025 | msn.comInnovation Pharma Stock Price, Quotes and Forecasts | OTC:IPIX | BenzingaMay 2, 2025 | benzinga.com“Sell Nvidia before earnings”Eric Fry just went live with one of his most controversial calls yet: “Sell Nvidia.” While Wall Street has been chasing the AI giant, Eric says its biggest customers are now its biggest competitors — and that could spell trouble ahead. Instead, he’s urging investors to consider a little-known hardware company that’s already starting to take off. In fact, while Nvidia has slipped over the past 30 days, this “off-the-radar” stock is up 18% — and Eric believes the run is just beginning.August 26 at 2:00 AM | InvestorPlace (Ad)Diaceutics Hosts Webinar on Precision Medicine InnovationNovember 5, 2024 | markets.businessinsider.comInnovation at a price: The hidden costs of antibiotic developmentOctober 16, 2024 | msn.comWaverley Pharma Inc. (WAVE.V) Stock Price, News, Quote & History - Yahoo FinanceSeptember 23, 2024 | finance.yahoo.comQPharma Launches New Website Celebrating 30 Years of Compliance and InnovationJuly 25, 2024 | tmcnet.com'Vital to promote innovation for growth in pharma sector'July 22, 2024 | msn.comSee More Headlines IPIX Stock Analysis - Frequently Asked Questions How have IPIX shares performed this year? Innovation Pharmaceuticals' stock was trading at $0.0001 at the beginning of 2025. Since then, IPIX shares have increased by 900.0% and is now trading at $0.0010. How do I buy shares of Innovation Pharmaceuticals? Shares of IPIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Innovation Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Innovation Pharmaceuticals investors own include Green Thumb Industries (GTBIF), Cannabix Technologies (BLOZF), Trulieve Cannabis (TCNNF), NVIDIA (NVDA), Planet 13 (PLNHF), Vaxart (VXRT) and CytoDyn (CYDY). Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry Biotechnology Sub-IndustryPharmaceutical Products Current SymbolOTCMKTS:IPIX CIK1355250 Webwww.cellceutix.com Phone(978) 921-4125FaxN/AEmployees4Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free Report This page (OTCMKTS:IPIX) was last updated on 8/26/2025 by MarketBeat.com Staff From Our PartnersWhat Steve Bannon revealed about Trump’s gold playA Trump advisor just said 3 words that could reset the dollar. It’s a gold move nobody saw coming—and your ...Reagan Gold Group | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredFed Decision Warning: How to Protect Your Wealth Before September 30th On September 17th, the Fed faces an impossible choice—and Wall Street insiders are already preparing for the...American Alternative | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredThink you missed gold’s boom? Think againIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredTake a look at this picture ...A strange investment secret — discovered just a few short weeks before this image was taken — correctly predic...Weiss Ratings | SponsoredElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Innovation Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Innovation Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.